Editorial Policy
TryTrutide is committed to accurate, evidence-rated, and transparently sourced coverage of retatrutide research, clinical trials, safety, and regulatory developments.
Last updated: September 2026Topic Selection
Topics are selected based on clinical significance, regulatory relevance, community interest, and evidence availability. We prioritize peer-reviewed research, Phase 2/3 trial data, FDA communications, and authoritative regulatory documents.
Sourcing Standards
Every factual claim is sourced to the most authoritative available source: FDA.gov, ClinicalTrials.gov, PubMed, NIH, peer-reviewed journals, DOI records, university research, official Eli Lilly communications, or official government documents. We do not use low-quality affiliate websites, research-peptide sellers, or unverified social media posts as evidence.
Writing & Review
Articles are written by TryTrutide editorial staff and may be reviewed by appropriately licensed clinicians where indicated. Every article displays its author, any medical reviewer, publication date, last review date, and last update date.
Evidence Rating
All research content is rated on the TruTide Evidence Scale (A–X). Ratings reflect the quality and type of evidence supporting each claim — from Phase 3 RCT data (A) to unsupported or potentially dangerous claims (X). Ratings are displayed prominently and explained in the Evidence Methodology.
Updates & Corrections
Content is updated when new evidence, regulatory decisions, or trial data become available. Corrections are handled per the Corrections Policy. Update dates are displayed on all articles.
Editorial Independence
TryTrutide editorial content is independent of advertising, sponsorship, and commercial relationships. We do not accept payment for editorial coverage. Advertising and sponsorship relationships, if any, are disclosed per the Advertising Policy.